Consider- ations for heart failure during the COVID-19 pandemic. J Am Coll Cardiol HF. 2020;8:681 91. 53. Baumwol J. I Need Help a mnemonic to aid timely referral in advanced heart failure. J Heart Lung Transplant. 2017;36:593 4. 54. Januzzi JL Jr., Camacho A, Pina IL, et al. Reverse cardiac remodeling and outcome after initiation of sacubitril/valsartan. Circ Heart Fail. 2020;13:e006946. 55. Halliday BP, Wassall R, Lota AS, et al. Withdrawal of pharmacological treatment for heart failure in pa- tients with recovered dilated cardiomyopathy (TRED- HF): an open-label, pilot, randomised trial. Lancet. 2019;393:61 73. 56. Wilcox JE, Fang JC, Margulies KB, et al. Heart failure with recovered left ventricular ejection fraction: JACC Scienti c Expert Panel. J Am Coll Cardiol. 2020; 76:719 34. 57. Karlstr m P, Alehagen U, Boman K, et al. Brain natriuretic peptide-guided treatment does not improve morbidity and mortality in extensively treated patients with chronic heart failure: responders to treatment have a signi cantly better outcome. Eur J Heart Fail. 2011;13:1096 103. 58. Ibrahim NE, Januzzi JL Jr. The future of biomarker- guided therapy for heart failure after the guiding evi- dence based therapy using biomarker intensi ed treatment in heart failure (GUIDE-IT) study. Curr Heart Fail Rep. 2018;15:37 43. 59. Daubert MA, Adams K, Yow E, et al. NT-proBNP goal achievement is associated with signi cant reverse remodelings and improved clinical outcomes in HFrEF. J Am Coll Cardiol HF. 2019;7:158 68. 60. Weiner RB, Baggish AL, Chen-Tournoux A, et al. Improvement in structural and functional echocardio- graphic parameters during chronic heart failure therapy guided by natriuretic peptides: mechanistic insights from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) study. Eur J Heart Fail. 2013;15:342 51. 61. Langenickel TH, Dole WP. Angiotensin receptor- neprilysin inhibition with LCZ696: a novel approach for the treatment of heart failure. 